<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We performed a randomized, controlled study comparing the prophylactic effects of capsule forms of <z:chebi fb="2" ids="46081">fluconazole</z:chebi> (n = 110) and <z:chebi fb="0" ids="6076">itraconazole</z:chebi> (n = 108) in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) during and after chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>There were 4 cases with possible <z:e sem="disease" ids="C0553576" disease_type="Disease or Syndrome" abbrv="">systemic fungal infection</z:e> in the <z:chebi fb="0" ids="6076">itraconazole</z:chebi> group, and there were 8 possible and 3 probable cases in the <z:chebi fb="2" ids="46081">fluconazole</z:chebi> group </plain></SENT>
<SENT sid="2" pm="."><plain>Adverse events did not significantly differ in the 2 groups </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or in the remission-induction phase of chemotherapy, the numbers of cases with probable or possible <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were lower in the <z:chebi fb="0" ids="6076">itraconazole</z:chebi> group than in the <z:chebi fb="2" ids="46081">fluconazole</z:chebi> group, whereas no difference was seen in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or in the consolidation phase of therapy </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with neutrophil counts of &gt;0.1 x 10(9)/L lasting for more than 4 weeks, the frequency of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in the <z:chebi fb="2" ids="46081">fluconazole</z:chebi> group (5 of 9 patients) was significantly higher than in the <z:chebi fb="0" ids="6076">itraconazole</z:chebi> group (0 of 7 patients; P = .03) </plain></SENT>
<SENT sid="5" pm="."><plain>Our results suggest that both drugs were well tolerated in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who received chemotherapy and that the efficacy of <z:chebi fb="0" ids="6076">itraconazole</z:chebi> for prophylaxis against systemic <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal disease</z:e> is not inferior to that of <z:chebi fb="2" ids="46081">fluconazole</z:chebi> </plain></SENT>
</text></document>